Exploration of TCM Comprehensive Treatment of Irritable Bowel Syndrome Based on Pathophysiological Mechanism
- PMID: 40529345
- PMCID: PMC12170834
- DOI: 10.2147/IJGM.S513906
Exploration of TCM Comprehensive Treatment of Irritable Bowel Syndrome Based on Pathophysiological Mechanism
Abstract
Irritable bowel syndrome (IBS) is a gastrointestinal disorder that is characterized by abdominal pain and altered bowel habits. The clinical manifestations of IBS include abdominal discomfort; irregular bowel movements; potential bleeding; and various symptoms associated with somatic, visceral, and psychiatric conditions. Presently, the diagnosis of IBS relies on symptomatology and the exclusion of other organic disorders, while treatment modalities include pharmacological interventions targeting primary symptoms, dietary modifications, and psychotherapy. Although the underlying mechanisms contributing to morbidity in IBS remain inadequately understood, potential etiological factors include increased epithelial cell permeability, biological irregularities, inflammation, visceral hypersensitivity, genetic and epigenetic influences, and altered brain-gut interactions. IBS significantly diminishes the quality of life and imposes substantial burdens on patients, healthcare providers, and healthcare systems. Recent academic research has indicated that traditional Chinese medicine plays an increasingly significant role in IBS management. This study aimed to investigate the efficacy and safety of Traditional Chinese Medicine (TCM) in treating IBS, focusing on the pathophysiological mechanisms underlying the disorder, to provide insights into a promising complementary approach for managing IBS, with potential applications in clinical practice to improve symptom management and patient quality of life. Further research into the specific mechanisms of TCM in IBS treatment could pave the way for the development of targeted therapeutic strategies.
Keywords: IBS; TCM; abdominal pain; defecation disorder; diarrhea.
© 2025 Xu et al.
Conflict of interest statement
The authors declare that they have no affiliation with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript.
Figures
Similar articles
-
Efficacy and safety of Chinese botanical drug Si Shen Wan in irritable bowel syndrome: a meta-analysis and trial sequential analysis of randomized controlled trials.Front Pharmacol. 2025 Jun 2;16:1534904. doi: 10.3389/fphar.2025.1534904. eCollection 2025. Front Pharmacol. 2025. PMID: 40529486 Free PMC article.
-
A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial.Lancet Gastroenterol Hepatol. 2024 Jun;9(6):507-520. doi: 10.1016/S2468-1253(24)00045-1. Epub 2024 Apr 18. Lancet Gastroenterol Hepatol. 2024. PMID: 38643782 Clinical Trial.
-
[An Intestinal Metabolite Exacerbates Stress-induced Diarrhea].Yakugaku Zasshi. 2025;145(8):667-672. doi: 10.1248/yakushi.24-00190-2. Yakugaku Zasshi. 2025. PMID: 40754409 Review. Japanese.
-
Irritable Bowel Syndrome.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30521231 Free Books & Documents.
-
Evaluation of the combined use of linaclotide and probiotics on clinical treatment efficacy and quality of life in patients with constipation-predominant irritable bowel syndrome.Am J Transl Res. 2025 May 15;17(5):3333-3344. doi: 10.62347/GNSB4367. eCollection 2025. Am J Transl Res. 2025. PMID: 40535661 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources